Literature DB >> 19053535

A versatile bifunctional dendritic cell targeting vaccine vector.

Welson W Wang1, Dipankar Das, Mavanur R Suresh.   

Abstract

We have developed an efficient versatile in vivo dendritic cell (DC) targeting vector for delivering different classes of antigens such as proteins, peptide, glycolipids and naked DNA for vaccine applications. A single chain antibody (scFv) that recognizes DEC-205 receptor of DC was fused with a core-streptavidin domain and expressed in Escherichia coli using the T7 expression system. The bifunctional fusion protein (bfFp) was expressed as a periplasmic soluble protein and affinity-purified in its monomeric form. The bifunctional activity against DEC-205 and biotin was characterized by ELISA and Western blot. In vivo DC targeting of a diverse group of biotinylated antigens such as viral and bacterial proteins, a cancer peptide, gangliosides and DNA of certain infectious diseases was conducted in mice. Results show that in the presence of bfFp and costimulatory anti-CD40 mAb, both humoral and cell-mediated responses were augmented in either the single antigen or multiple antigen targeting strategy. Lastly, bfFp based DC targeting of antigens in low doses may be a useful strategy for the design of monovalent or polyvalent vaccines for the masses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19053535      PMCID: PMC2678937          DOI: 10.1021/mp800111a

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  49 in total

Review 1.  C-type lectin receptors on dendritic cells and Langerhans cells.

Authors:  Carl G Figdor; Yvette van Kooyk; Gosse J Adema
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

Review 2.  Antibody engineering and modification technologies.

Authors:  David Filpula
Journal:  Biomol Eng       Date:  2007-03-31

3.  A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.

Authors:  J Schultz; Y Lin; J Sanderson; Y Zuo; D Stone; R Mallett; S Wilbert; D Axworthy
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

4.  Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.

Authors:  T Gilewski; S Adluri; G Ragupathi; S Zhang; T J Yao; K Panageas; M Moynahan; A Houghton; L Norton; P O Livingston
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

5.  Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy.

Authors:  Scott S Graves; Erica Dearstyne; Yukang Lin; Yuting Zuo; James Sanderson; Jody Schultz; Anastasia Pantalias; David Gray; Don Axworthy; H Mark Jones; Karen Auditore-Hargreaves
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

6.  Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.

Authors:  Meili Zhang; Zhuo Zhang; Kayhan Garmestani; Jody Schultz; Donald B Axworthy; Carolyn K Goldman; Martin W Brechbiel; Jorge A Carrasquillo; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-04       Impact factor: 11.205

7.  An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.

Authors:  Lixin Zhang; Yucheng Tang; Hakan Akbulut; Daniel Zelterman; Phyllis-Jean Linton; Albert B Deisseroth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-25       Impact factor: 11.205

8.  CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

Authors:  J M den Haan; S M Lehar; M J Bevan
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

9.  Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.

Authors:  D Hawiger; K Inaba; Y Dorsett; M Guo; K Mahnke; M Rivera; J V Ravetch; R M Steinman; M C Nussenzweig
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

10.  Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.

Authors:  Laura Bonifaz; David Bonnyay; Karsten Mahnke; Miguel Rivera; Michel C Nussenzweig; Ralph M Steinman
Journal:  J Exp Med       Date:  2002-12-16       Impact factor: 14.307

View more
  5 in total

1.  Complexes of streptavidin-fused antigens with biotinylated antibodies targeting receptors on dendritic cell surface: a novel tool for induction of specific T-cell immune responses.

Authors:  Ondrej Stanek; Irena Linhartova; Laleh Majlessi; Claude Leclerc; Peter Sebo
Journal:  Mol Biotechnol       Date:  2012-07       Impact factor: 2.695

Review 2.  The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis.

Authors:  Akshay Jain; Kun Cheng
Journal:  J Control Release       Date:  2016-11-16       Impact factor: 9.776

3.  Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.

Authors:  Dharmendra Raghuwanshi; Vivek Mishra; Dipankar Das; Kamaljit Kaur; Mavanur R Suresh
Journal:  Mol Pharm       Date:  2012-03-20       Impact factor: 4.939

4.  Targeting Dendritic Cells in vivo for Cancer Therapy.

Authors:  Irina Caminschi; Eugene Maraskovsky; William Ross Heath
Journal:  Front Immunol       Date:  2012-02-07       Impact factor: 7.561

5.  Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.

Authors:  Yingying Xu; Pak-Wai Yuen; Jenny Ka-Wing Lam
Journal:  Pharmaceutics       Date:  2014-07-10       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.